Narrow search
Showing 1 - 10 of 3,510
Cover Image
The welfare impact of parallel imports : a structural approach applied to the German market for oral anti-diabetics
Duso, Tomaso; Herr, Annika; Suppliet, Moritz - 2014
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010338113
Cover Image
The welfare impact of parallel imports : a structural approach applied to the German market for oral anti-diabetics
Duso, Tomaso; Herr, Annika; Suppliet, Moritz - 2014
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 anti-diabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010339071
Cover Image
Reference pricing and cost-sharing : theory and evidence on German off-patent drugs ; conference paper
Herr, Annika; Stühmeier, Torben; Wenzel, Tobias - 2014
-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference …
Persistent link: https://www.econbiz.de/10010489291
Cover Image
The welfare impact of parallel imports : a structural approach applied to the German market for oral antidiabetics ; conference paper
Duso, Tomaso; Herr, Annika; Suppliet, Moritz - 2014 - Preliminary version
We investigate the welfare impact of parallel imports using a large panel data set containing monthly information on sales, ex-factory prices, and further product characteristics for all 700 antidiabetic drugs sold in Germany between 2004 and 2010. We estimate a two-stage nested logit model of...
Persistent link: https://www.econbiz.de/10010481411
Cover Image
Parallel imports and manufacturer rebates : evidence from Germany
Birg, Laura - 2019
pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …
Persistent link: https://www.econbiz.de/10011949028
Cover Image
A pharmaceutical innovation : is it worth the money? Whose money?
Sennhauser, Michèle; Zweifel, Peter - 2009
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance. A discrete choice experiment (DCE) was conducted in Germany to measure preferences for modern insulin therapy. Of the 1,100 individuals...
Persistent link: https://www.econbiz.de/10003900791
Cover Image
Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany
Herr, Annika; Suppliet, Moritz - 2012
Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …
Persistent link: https://www.econbiz.de/10009522774
Cover Image
The Effects of Reference Pricing on Ex-Factory Prices of Rx Drugs in Germany - a Panel Data Approach
Augurzky, Boris - 2006
This paper examines effects of reference pricing for prescription drugs in German social health insurance based on econometric panel data methods. We analyze the effect on ex-factory prices. Moreover, we investigate whether manufacturers adapt prices of their products not subject to reference...
Persistent link: https://www.econbiz.de/10012732944
Cover Image
Cost containment and managed care : evidence from German macro data
Ehlert, Andree; Oberschachtsiek, Dirk; Prawda, Stefan - 2013
The major German health care reforms undertaken since the late 1990s resulted in the adoption of selective contracting mechanisms in a formerly sectorally separated health care system. These reforms marked the launch of managed care in Germany that is expected to yield both a higher quality of...
Persistent link: https://www.econbiz.de/10010189584
Cover Image
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25
Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …
Persistent link: https://www.econbiz.de/10012291135